By participating in HOPA’s 15th Annual Conference, attendees will increase their ability to
- describe current controversies relating to the screening and treatment of patients with solid tumors and hematologic malignancies
- apply new and emerging therapies for hematology and oncology patients to clinical practice
- interpret recent developments in the medical literature regarding hematology/oncology medications.
About the Continuing Pharmacy Education Program
The purpose of the Hematology/Oncology Pharmacy Association’s Continuing Pharmacy Education (CPE) Program is to provide members with opportunities for lifelong learning and assistance in fulfilling their maintenance of certification and licensure requirements, thereby promoting excellence in the provision of pharmacy care.
Definition of Continuing Pharmacy Education
Continuing education for those in the profession of pharmacy is a structured educational activity designed or intended to support the continuing development of pharmacists and pharmacy technicians to maintain and enhance their competence. CPE should promote problem solving and critical thinking and be applicable to the practice of pharmacy.
Definition of Commercial Bias
Commercial bias is a personal judgment in favor of a specific proprietary business interest or commercial interest.
Learner’s Bill of Rights
HOPA recognizes that you are a lifelong learner who has chosen to engage in CPE to identify or fill a gap in knowledge or skill and to attain or enhance a desired competency. You have the right to expect that, as part of HOPA’s fulfillment of its duties to you as a learner, your CPE experience with HOPA will include the following:
- promotes improvements or quality in health care
- is current, valid, reliable, accurate, and evidence based
- addresses the stated objectives or purpose
- is driven by and based on an independent survey and analysis of learners’ needs, not commercial interests
- has been reviewed for bias and scientific rigor
- offers balanced presentations that are free of commercial bias
- is vetted through a process that resolves any conflicts of interest of planners and faculty
- is evaluated for its effectiveness in meeting the identified educational need
A learning environment that
- is based on adult learning principles that support the use of various modalities
- supports learners’ abilities to meet their individual needs
- respects and attends to any special needs of the learners
- respects the diversity of groups of learners
- is free of promotional, commercial, and sales activities
- relevant financial relationships that planners, teachers, and authors have with commercial interests related to the content of the activity
- commercial support (funding or in-kind resources) of this activity.
Independence in CPE
The mission of HOPA’s CPE program is to improve patient care and healthcare outcomes by maintaining, developing, and enhancing medical knowledge, patient care, interpersonal and communication skills, and professionalism. As a provider accredited by the Accreditation Council for Pharmacy Education and in support of this mission, HOPA is dedicated to providing CPE that is independent, fair, balanced, objective, and free of commercial bias.
HOPA employs several strategies to ensure that these standards will be met. HOPA’s Annual Conference Committee members submit and consider their own disclosure information and recuse themselves from planning educational activities if they have conflicts related to the subject area covered. When developing an educational program, the committee reviews applications and disclosure-of-interest forms, along with needs assessment and evaluative data from past activities. Potential participants receive detailed guidelines on components necessary to ensure independence in CPE activities and to resolve conflicts, as itemized below.
Statement of Need and Program Overview
HOPA organizes an annual conference for hematology/oncology pharmacy practitioners to educate attendees about emerging research and new treatment regimens, provide clinical updates on treatment of tumor types and new supportive care therapies, and present an overview of common clinical and technical issues in the hematology/oncology clinical setting. The overall goal of educating oncology pharmacy practitioners about current developments is to improve the efficiency of healthcare delivery while maintaining a high quality of patient care. Hematology/oncology practitioners who have been informed about the latest developments in clinical trials, therapeutic regimens, treatment guidelines, and emerging technologies will be well positioned to participate in clinical decision making and healthcare initiatives that have a direct and positive impact on care management for cancer patients.
Objectives of the 2019 conference include educating attendees about topics of emerging interest in care management for cancer patients and practical issues that pharmacists face while delivering cancer care. Decisions about topics, scheduling, venue, and speakers for HOPA’s 15th Annual Conference were made on the basis of therapeutic advances in hematology/oncology, current medical news, input from HOPA’s planning committees, and suggestions from last year’s participants.
The primary target audience of the HOPA Annual Conference is its pharmacist members. Secondary audiences are pharmacy residents and other pharmacy healthcare professionals.
Disclosure of Conflicts of Interest
HOPA assesses conflicts of interest with its faculty, planners, managers, and other individuals who are in a position to control the content of CPE activities. All identified potential conflicts of interest are thoroughly reviewed, with consideration given to balance, the scientific objectivity of studies used in the activity, and recommendations for patient care. HOPA is committed to providing its learners with high-quality CPE activities and related materials that promote improvements or quality in health care and not specific proprietary commercial interests. The faculty’s disclosures of conflicts of interest are available for review.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. HOPA and its faculty, planners, managers, and commercial supporters do not recommend the use of any agent outside the labeled indications. The opinions expressed in the educational activities are those of the faculty and do not necessarily represent the views of HOPA or any other organizational or commercial entities.
Resolution of Conflicts of Interest
In accordance with the ACPE Standards for Commercial Support of CPE, the Hematology/Oncology Pharmacy Association has, prior to the planning and implementation of this CPE activity, implemented mechanisms to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CPE activity.
Hematology/Oncology Pharmacy Association Accreditation Statement
The Hematology/Oncology Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
The Hematology/Oncology Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this program will provide up to 16.75 credits for the conference, and up to 20.75 credits including credit for the preconference session. Successful completion includes participating in the activity and completing an online session evaluation form. A statement of participation will be available online immediately following successful completion of the activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications because of dangers in their use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Council for Pharmacy Education Credit
To claim ACPE credit, attendees should complete the evaluations and posttests online through Conference Web Central at hoparx.org. Online evaluation of sessions should be completed at the end of each day at the Cyber Cafe stations located in the registration area. A CPE certificate may be created online, but it should not be created until sessions have been evaluated and credit has been claimed for all conference sessions attended. The 7 BCOP specialty sessions are open to all conference attendees for CPE credit.
In accordance with the pharmacy credit reporting program of the National Association of Boards of Pharmacy (NABP), participants have 60 days after the completion of the annual conference to submit an evaluation for the activity. To claim credit and to help HOPA assess future educational needs, attendees must complete the evaluation process by Thursday, May 30, 2019. After May 30, evaluations may no longer be submitted for credit. After the attendee’s completion of evaluations, HOPA will report the credits to a CPE Monitor for transmittance to NABP.
Board Certified Oncology Pharmacist Recertification Credit
Board Certified Oncology Pharmacist (BCOP) credit will be issued for individual BCOP sessions. New this year: upon registration, conference attendees will automatically be granted access to the BCOP posttests for the sessions presented at the 15th Annual Conference and will receive notification when the tests are available. To earn BCOP credit for these BCOP specialty sessions, you must take the BCOP posttests on or before September 30, 2019. HOPA will send notification of earned recertification credits to the Board of Pharmacy Specialties.